Since about one-third of patients with major depressive disorder (MDD) do not respond adequately to available antidepressants, there is a need for treatments based on novel mechanisms of action. Neuropeptide Y (NPY), a normal brain constituent, is reduced in cerebrospinal fluid of patients with MDD and post-traumatic stress disorder and in corresponding rodent models. Moreover, NPY administered centrally or intranasally rescues pathophysiology in these models. Consequently, we conducted the first, to our knowledge, controlled trial of NPY as a treatment for MDD.

中文翻译：

---

重度抑郁症患者鼻内神经肽 Y 的随机对照试验

由于大约三分之一的重度抑郁症 (MDD) 患者对可用的抗抑郁药没有足够的反应，因此需要基于新作用机制的治疗。神经肽 Y (NPY) 是一种正常的大脑成分，在 MDD 和创伤后应激障碍患者的脑脊液以及相应的啮齿动物模型中减少。此外，在这些模型中，中央或鼻内给药的 NPY 可以挽救病理生理学。因此，据我们所知，我们对 NPY 作为 MDD 的治疗进行了第一次对照试验。